Combination Therapies with SHP2 Inhibitors to Treat KRAS Mutant Cancers

Time: 9:40 am
day: Day Two


• Exploring the potential of SHP2i & G12Ci combination for KRAS G12C mutant cancers
• Benchmarking the effectivity of combining SHP2i & MAPKi to target KRAS mutant cancers
• Adopting CDK4/6i within combination for effective KRAS therapy combination approach for effective KRAS therapy